Morepen Laboratories Limited has informed the Exchange regarding Board meeting held on August 06, 2025.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories' Board, which met on August 6, 2025, approved the unaudited Q1 FY26 results (quarter ended June 30, 2025). On a consolidated basis, total income fell to Rs. 42,964.73 lakhs from Rs. 45,864.27 lakhs in Q1 FY25, while net profit (after minority interest) dropped sharply to Rs. 1,074.83 lakhs from Rs. 3,616.79 lakhs, with EPS at Rs. 0.20 vs Rs. 0.71. Standalone net profit also declined steeply to Rs. 806.12 lakhs (EPS Rs. 0.15) from Rs. 3,504.96 lakhs a year ago. The Board fixed August 30, 2025 as the record date for a final dividend (subject to AGM approval). It also approved the extension of time for hiving off the Medical Devices Business into subsidiary Morepen Medipath Limited on a slump sale basis. Additionally, Mr. Sanjay Suri was re-appointed as Whole-Time Director for three years, and M/s. PD and Associates was appointed as Secretarial Auditor for five years (FY26–FY30).
The steep YoY drop in profits despite broadly stable revenues is likely to weigh negatively on the stock in the short term. The proposed final dividend and AGM-related approvals are routine; however, the de-subsidiarisation of Dr. Morepen (shareholding cut from 80% to 19.94%) and the planned Medical Devices hive-off signal meaningful corporate restructuring that shareholders should track closely.